{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:44Z","timestamp":1782417524695,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2703100"],"award-info":[{"award-number":["2022YFC2703100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jchromb.2023.123900","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T01:01:24Z","timestamp":1696122084000},"page":"123900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Rapid ultra-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of three characteristic urinary saccharide metabolites in patients with glycogen storage diseases (type \u2160b and \u2161)"],"prefix":"10.1016","volume":"1229","author":[{"given":"Jianwei","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123900_b0005","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1093\/hmg\/ddz133","article-title":"Gene therapy for glycogen storage diseases","volume":"28","author":"Kishnani","year":"2019","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.jchromb.2023.123900_b0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med"},{"key":"10.1016\/j.jchromb.2023.123900_b0015","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.1816143116","article-title":"Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency","volume":"116","author":"Veiga-da-Cunha","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.jchromb.2023.123900_b0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal. Biochem"},{"key":"10.1016\/j.jchromb.2023.123900_b0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","article-title":"Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening","volume":"135","author":"Huggins","year":"2022","journal-title":"Mol. Genet. Metab"},{"key":"10.1016\/j.jchromb.2023.123900_b0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: A systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab"},{"key":"10.1016\/j.jchromb.2023.123900_b0035","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jchromb.2023.123900_b0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated Gene Therapy for Pompe Disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J. Neuromuscul. Dis"},{"key":"10.1016\/j.jchromb.2023.123900_b0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2362.1974.tb00416.x","article-title":"Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe's disease)","volume":"4","author":"Hallgren","year":"1974","journal-title":"Eur. J. Clin. Invest"},{"key":"10.1016\/j.jchromb.2023.123900_b0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0140-6736(83)92122-0","article-title":"Increased urinary excretion of a glycogen-derived tetrasaccharide in heterozygotes with glycogen storage diseases type II and III","volume":"1","author":"Chester","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jchromb.2023.123900_b0055","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1373\/clinchem.2011.178319","article-title":"Rapid Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry Assay for a Characteristic Glycogen-Derived Tetrasaccharide in Pompe Disease and Other Glycogen Storage Diseases","volume":"58","author":"Sluiter","year":"2012","journal-title":"Clin. Chem"},{"key":"10.1016\/j.jchromb.2023.123900_b0060","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41436-020-0878-2","article-title":"The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases","volume":"22","author":"Heiner-Fokkema","year":"2020","journal-title":"Genet. Med"},{"key":"10.1016\/j.jchromb.2023.123900_b0065","first-page":"381","article-title":"The Action of Recombinant Human Lysosomal \u03b1-Glucosidase (rhGAA) on Human Liver Glycogen: Pathway to Complete Degradation","volume":"1","author":"Murray","year":"2021","journal-title":"Int. J. Transl. Med"},{"key":"10.1016\/j.jchromb.2023.123900_b0070","article-title":"The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb","volume":"29","author":"Resaz","year":"2021","journal-title":"Mol. Genet. Metab. Rep"},{"key":"10.1016\/j.jchromb.2023.123900_b0075","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood.2019004465","article-title":"Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor","volume":"136","author":"Wortmann","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jchromb.2023.123900_b0080","article-title":"Liver transplantation in glycogen storage disease type Ib: The role of SGLT2 inhibitors","volume":"35","author":"Murko","year":"2023","journal-title":"Mol. Genet. Metab. Rep"},{"key":"10.1016\/j.jchromb.2023.123900_b0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","article-title":"Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre","volume":"17","author":"Halligan","year":"2022","journal-title":"Orphanet. J. Rare. Dis"},{"key":"10.1016\/j.jchromb.2023.123900_b0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0009-8981(83)90200-0","article-title":"Thin-layer chromatography of oligosaccharides in urine as a rapid indication for the diagnosis of lysosomal acid maltase deficiency (Pompe's disease)","volume":"134","author":"Blom","year":"1983","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2023.123900_b0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","article-title":"Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases","volume":"35","author":"Manwaring","year":"2012","journal-title":"J. Inherit. Metab. Dis"},{"key":"10.1016\/j.jchromb.2023.123900_b0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem"},{"key":"10.1016\/j.jchromb.2023.123900_b0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/GIM.0b013e3181a87867","article-title":"Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker","volume":"11","author":"Young","year":"2009","journal-title":"Genet. Med"},{"key":"10.1016\/j.jchromb.2023.123900_b0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.forsciint.2012.05.010","article-title":"Clinical and forensic examinations of glycemic marker 1, 5-anhydroglucitol by means of high performance liquid chromatography tandem mass spectrometry","volume":"222","author":"Hess","year":"2012","journal-title":"Forensic. Sci. Int"},{"key":"10.1016\/j.jchromb.2023.123900_b0115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2015.238626","article-title":"CLSI C62-A: A New Standard for Clinical Mass Spectrometry","volume":"62","author":"Lynch","year":"2016","journal-title":"Clin. Chem"},{"key":"10.1016\/j.jchromb.2023.123900_b0120","unstructured":"U. S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CMV). Guidance for Industry: Bioanalytical Method Validation; Food and Drug Administration: Silver Spring, MD, USA, 2018."},{"key":"10.1016\/j.jchromb.2023.123900_b0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jat\/bky042","article-title":"Adduct Formation-Supported Two-Way Electrospray Ionization Strategy for the Determination of Urinary Creatinine Concentration with LC\u2013MS-MS in Abstinence Control","volume":"42","author":"Dziadosz","year":"2018","journal-title":"J. Anal. Toxicol"},{"key":"10.1016\/j.jchromb.2023.123900_b0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol. Genet. Metab."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:14:09Z","timestamp":1761606849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":26,"alternative-id":["S1570023223003100"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123900","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid ultra-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of three characteristic urinary saccharide metabolites in patients with glycogen storage diseases (type \u2160b and \u2161)","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123900"}}